FDA approves new indication for semaglutide to reduce cardiovascular risk in diabetic patients
Novo Nordisk announced that the FDA has approved a new indication of 0.5 mg or 1 mg of Ozempic (semaglutide) for reducing the risk of major adverse cardiovascular events (MACE), …